Epilepsy Devices Market: Tech Trends 2022-2028

1
Epilepsy Devices Market Tech Trends
2022-2028 According to the WHO, epilepsy is a
chronic brain disorder that affects 50 million
individuals, making it one of the most prevalent
neurological conditions worldwide. It is
estimated that with access to early detection and
appropriate care, 70 of the population diagnosed
with epilepsy may live seizure-free. According to
our estimates, the global epilepsy devices market
was valued at 669.73 million in 2021 and is
expected to reach 1157.58 million by 2028,
growing at a CAGR of 8.16 during the forecast
period 2022-2028. Government institutions
worldwide are focused on starting initiatives to
create innovative epilepsy devices with AI and
machine learning integration. Additionally,
organizations that support research need to
encourage high-quality comparative efficacy
trials and sufficient data to guide therapeutic
practice in epilepsy. As a result of these
technologically advanced equipment and increasing
drug trials, the market for epilepsy devices is
anticipated to grow throughout the forecast
period.

• Epilepsy Devices - Key Detection Methodologies
• Currently, several wearable technologies can
  detect seizures, collect data, and alert
  caregivers. Although with technological
  advancements, the ability to detect
  seizure-related alterations increases. Top trends
  backing this tech boom include
• Wearable devices are estimated to be the
  fastest-growing device type during the forecast
  period. Monitoring epileptic patients is crucial,
  as 20 of epileptics only have seizures while
  asleep, 40 only have seizures while awake, and
  35 have seizures both when they are awake and
  asleep. With technologically advanced
  non-invasive wearable sensors, measuring
  accelerometry, photoplethysmography (PPG),
  electrodermal activity (EDA),

2

• electromyography (EMG), and other signals outside
  of the conventional clinical environment have
  become effective.
• Vagus Nerve Stimulation (VNS) has emerged as the
  fastest-growing application category. VNS Therapy
  has been approved by the U.S. Food and Drug
  Administration (FDA) as an add- on therapy for
  age 4 years and above to treat drug-resistant
  epilepsy or refractory epilepsy. VNS has been
  reportedly beneficial in many patients, including
  the ones with posttraumatic epilepsy (PTE). PTE
  is a common consequence of traumatic brain injury
  and accounts for about 20 of symptomatic
  epilepsy cases.
• As per estimates, Electroencephalography lead the
  detection and prediction devices type segment in
  2021 and is expected to maintain its stronghold
  during the forecast period. There is growing
  interest in wearable or mobile EEG solutions that
  allow long-term EEG monitoring in an easy-to-use
  format. Despite the availability of these new EEG
  solutions, their adoption is still limited in
  clinical practice, mainly because of the
  unfamiliarity of healthcare and biomedical
  research sectors with the technology and its
  application.
• Strategic Initiatives and Government Approvals
• Different end-users, such as homecare settings,
  hospitals, and clinics, are utilizing epilepsy
  devices. The manufacturers of epilepsy monitoring
  devices are likely to gain prominent business
  opportunities from the hospital clinics segment
  owing to the rise in the use of EEG monitoring
  and emergency medical services.
• The government authorities of several developing
  nations, including India and China, are focusing
  on developing sturdy healthcare infrastructure.
  As a result, operating players are expected to
  gain sizable growth prospects in the region
  during the forecast period. Owing to this, the
  Asia

Pacific epilepsy devices market is anticipated to
witness the fastest growth with a CAGR of 8.38
Kommentar A1 Hyperlink this Frame with revenue
statement
throughout the forecast period.

• In addition, companies are also focusing on
  launching novel devices for children. Moreover,
  companies are also using organic and inorganic
  strategies, including mergers and acquisitions,
  to stay ahead of the competition. Some of these
  include
• In September 2022, Boston Scientific
  Corporations current-generation WATCHMAN FLX
  Left Atrial Appendage Closure (LAAC) Device
  received U.S. Food and Drug Administration (FDA)
  approval to expand the instructions for use
  labeling. The company also received FDA 510(k)
  clearance for the EMBOLD Fibered Detachable Coil,
  which reduces the blood flow rate in the
  peripheral vasculature.
• In July 2022, Medtronic PLC received FDA 510(k)
  clearance for its UNiD Spine Analyzer v4.0
  planning platform to leverage machine learning.
• In November 2021, NeuroPace, Inc. received an
  Investigational Device Exemption (IDE) from the
  FDA to study the companys RNS System to treat
  primary generalized epilepsy in patients aged 12
  and above.
• Way Forward
• With technological advancements, epilepsy
  detection devices with exceptionally low false
  alarm rates have recently been developed. They
  are based on computationally intensive algorithms
  and employed in implanted systems for
  pre-surgical monitoring. Recent research has
  produced encouraging findings for probabilistic
  seizure risk projections using long-term wearable
  technology

3
and electronic seizure diaries. The symptoms,
mood, and cognitive function of an individual may
also have predictive significance. Therefore,
technological advances in non-invasive wearable
sensors are anticipated to create growth
opportunities for the epilepsy devices
market. FAQ Q1) What are the key end-users of
the epilepsy devices market? The key end-users in
the epilepsy devices market include hospitals
clinics, neurology centers, homecare settings,
and other end-users. Q2) Which region leads the
global epilepsy devices market? North America
leads the global epilepsy devices market.